Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
23 studies found for:    J591
Show Display Options
Rank Status Study
1 Unknown  Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Docetaxel;   Drug: Prednisone;   Drug: 177Lu-J591
2 Unknown  Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 Antibody
Condition: Prostate Cancer
Intervention: Drug: 117Lu-J591
3 Recruiting 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: 177Lu-J591;   Drug: Ketoconazole;   Drug: Hydrocortisone;   Drug: 111In-J591
4 Unknown  177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
Conditions: Kidney Cancer;   Head and Neck Cancer;   Breast Cancer;   Non-small Cell Lung Cancer;   Colorectal Cancer;   Pancreatic Cancer;   Ovarian Cancer;   Esophageal Cancer;   Gliomas
Intervention: Drug: 177Lu-J591
5 Completed Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu -J591)
6 Completed Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2
Condition: Prostatic Neoplasms
Interventions: Drug: Monoclonal Antibody J591;   Drug: Recombinant Interleukin-2
7 Completed Radiolabeled Monoclonal Antibody in Treating Patients With Progressive Metastatic Androgen-Independent Adenocarcinoma (Cancer) of the Prostate
Condition: Prostate Cancer
Intervention: Radiation: lutetium Lu 177 monoclonal antibody J591
8 Completed Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer
Condition: Prostate Cancer
Intervention: Biological: monoclonal antibody huJ591
9 Completed Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: monoclonal antibody muJ591;   Radiation: iodine I 131 monoclonal antibody muJ591
10 Active, not recruiting Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: 89Zr-DFO-huJ591
11 Recruiting PMS of Trazenta on the Long-term Use as Add-on Therapy
Condition: Diabetes Mellitus, Type 2
Intervention: Drug: Trazenta
12 Terminated Phase III Acute Coronary Syndrome
Condition: Acute Coronary Syndrome
Interventions: Drug: Apixaban;   Drug: Placebo
13 Active, not recruiting Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: fluticasone furoate/vilanterol;   Drug: fluticasone furoate;   Drug: vilanterol;   Other: Placebo
14 Completed MICHELANGELO OASIS-6 : Fondaparinux in ST Elevation Myocardial Infarction
Conditions: Myocardial Infarction;   ST-elevation Myocardial Infarction;   Acute Coronary Syndrome;   Acute Myocardial Infarction
Interventions: Drug: Fondaparinux - UFH indicated;   Other: Control - UFH not indicated;   Drug: fondaparinux - UFH not indicated;   Drug: Control - UFH
15 Completed Post-marketing Study of Monteplase ("Cleactor") in Patients With Acute Pulmonary Embolism
Condition: Pulmonary Embolism
Intervention: Drug: Monteplase
16 Completed
Has Results
Safety and Efficacy of Mometasone Furoate Delivered Via Concept1 Device or Twisthaler® Device in Adult and Adolescent Patients With Persistent Asthma
Condition: Asthma
Interventions: Drug: Mometasone furoate;   Device: Concept 1;   Device: Twisthaler
17 Recruiting A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.
Condition: Cardiovascular Diseases
Interventions: Drug: AMR101;   Drug: Placebo
18 Completed Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Drug: cisplatin;   Drug: etoposide;   Drug: vinblastine sulfate;   Drug: vindesine;   Drug: vinorelbine tartrate;   Radiation: radiation therapy
19 Active, not recruiting A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Placebo;   Drug: erlotinib [Tarceva];   Drug: onartuzumab [MetMAb]
20 Terminated Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients
Conditions: Anemia;   Chronic Renal Insufficiency
Interventions: Drug: HX575 recombinant human erythropoietin alfa;   Drug: ERYPO

   Previous Page Studies Shown (1-20) Next Page (21-23) Show next page of results    Last Page
Indicates status has not been verified in more than two years